Detalle Publicación

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols

Autores: Ribera, J. (Autor de correspondencia); Granada, I.; Morgades, M.; González, T.; Ciudad, J.; Such, E.; Calasanz Abinzano, María José; Mercadal, S.; Coll, R.; González-Campos, J.; Tormo, M.; García-Cadenas, I.; Gil, C.; Cervera, M.; Barba, P.; Costa, D.; Ayala, R.; Bermúdez, A.; Orfao, A.; Ribera, J. M.; Programa Tratamiento Hemopatias Ma; Spanish Soc Hematology; SEHH
Título de la revista: BRITISH JOURNAL OF HAEMATOLOGY
ISSN: 0007-1048
Volumen: 196
Número: 3
Páginas: 670 - 675
Fecha de publicación: 2022
Resumen:
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBXI) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBXI showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBXI had a significantly higher cumulative incidence of relapse, especially among patients aged >= 35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
DOI: https://doi.org/10.1111/bjh.17844
Impacto:
2 citas en
Google Scholar